#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Aggregatibacter actinomycetemcomitans is a Gram-negative member of the human oral microbiota and is involved in human infections and diseases .
2-1	16-31	Aggregatibacter	person[2]	new[2]	coref	2-4[3_2]
2-2	32-53	actinomycetemcomitans	person[2]	new[2]	_	_
2-3	54-56	is	_	_	_	_
2-4	57-58	a	person[3]	giv[3]	_	_
2-5	59-72	Gram-negative	person[3]	giv[3]	_	_
2-6	73-79	member	person[3]	giv[3]	_	_
2-7	80-82	of	person[3]	giv[3]	_	_
2-8	83-86	the	person[3]|substance[4]	giv[3]|new[4]	_	_
2-9	87-92	human	person[3]|substance[4]	giv[3]|new[4]	_	_
2-10	93-97	oral	person[3]|substance[4]	giv[3]|new[4]	_	_
2-11	98-108	microbiota	person[3]|substance[4]	giv[3]|new[4]	_	_
2-12	109-112	and	_	_	_	_
2-13	113-115	is	_	_	_	_
2-14	116-124	involved	_	_	_	_
2-15	125-127	in	_	_	_	_
2-16	128-133	human	abstract[5]	new[5]	_	_
2-17	134-144	infections	abstract[5]	new[5]	_	_
2-18	145-148	and	_	_	_	_
2-19	149-157	diseases	abstract	new	coref	3-3[8_0]
2-20	158-159	.	_	_	_	_

#Text=One of these diseases is periodontitis , characterized by destruction of tooth-supporting periodontal tissues due to an inflammatory response .
3-1	160-163	One	person[7]	new[7]	coref	3-6[9_7]
3-2	164-166	of	person[7]	new[7]	_	_
3-3	167-172	these	person[7]|abstract[8]	new[7]|giv[8]	_	_
3-4	173-181	diseases	person[7]|abstract[8]	new[7]|giv[8]	_	_
3-5	182-184	is	_	_	_	_
3-6	185-198	periodontitis	person[9]	giv[9]	coref	9-27[0_9]
3-7	199-200	,	person[9]	giv[9]	_	_
3-8	201-214	characterized	person[9]	giv[9]	_	_
3-9	215-217	by	person[9]	giv[9]	_	_
3-10	218-229	destruction	person[9]|event[10]	giv[9]|new[10]	_	_
3-11	230-232	of	person[9]|event[10]	giv[9]|new[10]	_	_
3-12	233-249	tooth-supporting	person[9]|event[10]|object[11]	giv[9]|new[10]|new[11]	_	_
3-13	250-261	periodontal	person[9]|event[10]|object[11]	giv[9]|new[10]|new[11]	_	_
3-14	262-269	tissues	person[9]|event[10]|object[11]	giv[9]|new[10]|new[11]	_	_
3-15	270-273	due	person[9]	giv[9]	_	_
3-16	274-276	to	person[9]	giv[9]	_	_
3-17	277-279	an	person[9]|event[12]	giv[9]|new[12]	coref	5-8[27_12]
3-18	280-292	inflammatory	person[9]|event[12]	giv[9]|new[12]	_	_
3-19	293-301	response	person[9]|event[12]	giv[9]|new[12]	_	_
3-20	302-303	.	_	_	_	_

#Text=A. actinomycetemcomitans possesses several virulence factors , of which the production of the RTX ( repeats-in-toxin ) leukotoxin ( LtxA ) has received much attention .
4-1	304-306	A.	person|abstract[14]	new|new[14]	coref|coref	7-20|7-20[52_14]
4-2	307-328	actinomycetemcomitans	abstract[14]	new[14]	_	_
4-3	329-338	possesses	_	_	_	_
4-4	339-346	several	abstract[16]	new[16]	coref	16-49[150_16]
4-5	347-356	virulence	abstract|abstract[16]	new|new[16]	coref	7-35[59_0]
4-6	357-364	factors	abstract[16]	new[16]	_	_
4-7	365-366	,	abstract[16]	new[16]	_	_
4-8	367-369	of	abstract[16]	new[16]	_	_
4-9	370-375	which	abstract[16]	new[16]	_	_
4-10	376-379	the	abstract[16]|event[17]	new[16]|new[17]	coref	16-17[141_17]
4-11	380-390	production	abstract[16]|event[17]	new[16]|new[17]	_	_
4-12	391-393	of	abstract[16]|event[17]	new[16]|new[17]	_	_
4-13	394-397	the	abstract[16]|event[17]|substance[20]	new[16]|new[17]|new[20]	_	_
4-14	398-401	RTX	abstract[16]|event[17]|substance|substance[20]	new[16]|new[17]|new|new[20]	_	_
4-15	402-403	(	abstract[16]|event[17]|substance[20]	new[16]|new[17]|new[20]	_	_
4-16	404-420	repeats-in-toxin	abstract[16]|event[17]|abstract|substance[20]	new[16]|new[17]|new|new[20]	_	_
4-17	421-422	)	abstract[16]|event[17]|substance[20]	new[16]|new[17]|new[20]	_	_
4-18	423-433	leukotoxin	abstract[16]|event[17]|substance[20]	new[16]|new[17]|new[20]	_	_
4-19	434-435	(	abstract[16]	new[16]	_	_
4-20	436-440	LtxA	abstract[16]|abstract	new[16]|new	coref	5-1
4-21	441-442	)	abstract[16]	new[16]	_	_
4-22	443-446	has	abstract[16]	new[16]	_	_
4-23	447-455	received	abstract[16]	new[16]	_	_
4-24	456-460	much	abstract[16]|abstract[22]	new[16]|new[22]	_	_
4-25	461-470	attention	abstract[16]|abstract[22]	new[16]|new[22]	_	_
4-26	471-472	.	_	_	_	_

#Text=LtxA induces cell lysis , degranulation and an inflammatory response in human leukocytes by interaction with the β2-integrins in the cell membrane of human immune cells .
5-1	473-477	LtxA	abstract	giv	coref	6-10
5-2	478-485	induces	_	_	_	_
5-3	486-490	cell	place|abstract[25]	new|new[25]	coref|coref	5-21|11-9[0_25]
5-4	491-496	lysis	abstract[25]	new[25]	_	_
5-5	497-498	,	_	_	_	_
5-6	499-512	degranulation	event	new	_	_
5-7	513-516	and	_	_	_	_
5-8	517-519	an	event[27]	giv[27]	_	_
5-9	520-532	inflammatory	event[27]	giv[27]	_	_
5-10	533-541	response	event[27]	giv[27]	_	_
5-11	542-544	in	event[27]	giv[27]	_	_
5-12	545-550	human	event[27]|abstract[28]	giv[27]|new[28]	_	_
5-13	551-561	leukocytes	event[27]|abstract[28]	giv[27]|new[28]	_	_
5-14	562-564	by	_	_	_	_
5-15	565-576	interaction	event[29]	new[29]	_	_
5-16	577-581	with	event[29]	new[29]	_	_
5-17	582-585	the	event[29]|substance[30]	new[29]|new[30]	_	_
5-18	586-598	β2-integrins	event[29]|substance[30]	new[29]|new[30]	_	_
5-19	599-601	in	event[29]|substance[30]	new[29]|new[30]	_	_
5-20	602-605	the	event[29]|substance[30]|place[32]	new[29]|new[30]|new[32]	_	_
5-21	606-610	cell	event[29]|substance[30]|place|place[32]	new[29]|new[30]|giv|new[32]	coref	11-8
5-22	611-619	membrane	event[29]|substance[30]|place[32]	new[29]|new[30]|new[32]	_	_
5-23	620-622	of	event[29]|substance[30]|place[32]	new[29]|new[30]|new[32]	_	_
5-24	623-628	human	event[29]|substance[30]|place[32]|animal[33]	new[29]|new[30]|new[32]|new[33]	coref	11-13[90_33]
5-25	629-635	immune	event[29]|substance[30]|place[32]|animal[33]	new[29]|new[30]|new[32]|new[33]	_	_
5-26	636-641	cells	event[29]|substance[30]|place[32]|animal[33]	new[29]|new[30]|new[32]|new[33]	_	_
5-27	642-643	.	_	_	_	_

#Text=A 530-bp deletion in the promoter region of the LtxA gene operon was identified in the original JP2 strain , cultured from a young individual diagnosed with juvenile periodontitis .
6-1	644-645	A	event[35]	new[35]	coref	7-14[50_35]
6-2	646-652	530-bp	abstract|event[35]	new|new[35]	coref	7-15
6-3	653-661	deletion	event[35]	new[35]	_	_
6-4	662-664	in	event[35]	new[35]	_	_
6-5	665-668	the	event[35]|place[37]	new[35]|new[37]	_	_
6-6	669-677	promoter	event[35]|person|place[37]	new[35]|new|new[37]	_	_
6-7	678-684	region	event[35]|place[37]	new[35]|new[37]	_	_
6-8	685-687	of	event[35]|place[37]	new[35]|new[37]	_	_
6-9	688-691	the	event[35]|place[37]|abstract[40]	new[35]|new[37]|new[40]	_	_
6-10	692-696	LtxA	event[35]|place[37]|abstract|abstract[40]	new[35]|new[37]|giv|new[40]	coref	11-24[92_0]
6-11	697-701	gene	event[35]|place[37]|abstract|abstract[40]	new[35]|new[37]|new|new[40]	_	_
6-12	702-708	operon	event[35]|place[37]|abstract[40]	new[35]|new[37]|new[40]	_	_
6-13	709-712	was	_	_	_	_
6-14	713-723	identified	_	_	_	_
6-15	724-726	in	_	_	_	_
6-16	727-730	the	abstract[42]	new[42]	coref	11-41[98_42]
6-17	731-739	original	abstract[42]	new[42]	_	_
6-18	740-743	JP2	abstract|abstract[42]	new|new[42]	coref	7-28
6-19	744-750	strain	abstract[42]	new[42]	_	_
6-20	751-752	,	abstract[42]	new[42]	_	_
6-21	753-761	cultured	abstract[42]	new[42]	_	_
6-22	762-766	from	abstract[42]	new[42]	_	_
6-23	767-768	a	abstract[42]|person[43]	new[42]|new[43]	_	_
6-24	769-774	young	abstract[42]|person[43]	new[42]|new[43]	_	_
6-25	775-785	individual	abstract[42]|person[43]	new[42]|new[43]	_	_
6-26	786-795	diagnosed	abstract[42]|person[43]	new[42]|new[43]	_	_
6-27	796-800	with	abstract[42]|person[43]	new[42]|new[43]	_	_
6-28	801-809	juvenile	abstract[42]|person[43]|abstract[44]	new[42]|new[43]|new[44]	_	_
6-29	810-823	periodontitis	abstract[42]|person[43]|abstract[44]	new[42]|new[43]|new[44]	_	_
6-30	824-825	.	_	_	_	_

#Text=This discovery marked the beginning of an era , where the detection of the 530-bp deletion categorized highly leukotoxic A. actinomycetemcomitans strains as a member of the JP2 clone of A. actinomycetemcomitans , possessing enhanced virulence .
7-1	826-830	This	event[45]	new[45]	_	_
7-2	831-840	discovery	event[45]	new[45]	_	_
7-3	841-847	marked	_	_	_	_
7-4	848-851	the	event[46]	new[46]	_	_
7-5	852-861	beginning	event[46]	new[46]	_	_
7-6	862-864	of	event[46]	new[46]	_	_
7-7	865-867	an	event[46]|time[47]	new[46]|new[47]	_	_
7-8	868-871	era	event[46]|time[47]	new[46]|new[47]	_	_
7-9	872-873	,	event[46]|time[47]	new[46]|new[47]	_	_
7-10	874-879	where	event[46]|time[47]	new[46]|new[47]	_	_
7-11	880-883	the	event[46]|time[47]|event[48]	new[46]|new[47]|new[48]	_	_
7-12	884-893	detection	event[46]|time[47]|event[48]	new[46]|new[47]|new[48]	_	_
7-13	894-896	of	event[46]|time[47]|event[48]	new[46]|new[47]|new[48]	_	_
7-14	897-900	the	event[46]|time[47]|event[48]|event[50]	new[46]|new[47]|new[48]|giv[50]	coref	12-21[106_50]
7-15	901-907	530-bp	event[46]|time[47]|event[48]|abstract|event[50]	new[46]|new[47]|new[48]|giv|giv[50]	coref	12-22
7-16	908-916	deletion	event[46]|time[47]|event[48]|event[50]	new[46]|new[47]|new[48]|giv[50]	_	_
7-17	917-928	categorized	event[46]|time[47]	new[46]|new[47]	_	_
7-18	929-935	highly	event[46]|time[47]|abstract[53]	new[46]|new[47]|new[53]	coref	13-3[113_53]
7-19	936-946	leukotoxic	event[46]|time[47]|abstract[53]	new[46]|new[47]|new[53]	_	_
7-20	947-949	A.	event[46]|time[47]|person|abstract[52]|abstract[53]	new[46]|new[47]|giv|giv[52]|new[53]	coref|coref	7-31|7-31[58_52]
7-21	950-971	actinomycetemcomitans	event[46]|time[47]|abstract[52]|abstract[53]	new[46]|new[47]|giv[52]|new[53]	_	_
7-22	972-979	strains	event[46]|time[47]|abstract[53]	new[46]|new[47]|new[53]	_	_
7-23	980-982	as	event[46]|time[47]	new[46]|new[47]	_	_
7-24	983-984	a	event[46]|time[47]|person[54]	new[46]|new[47]|new[54]	_	_
7-25	985-991	member	event[46]|time[47]|person[54]	new[46]|new[47]|new[54]	_	_
7-26	992-994	of	event[46]|time[47]|person[54]	new[46]|new[47]|new[54]	_	_
7-27	995-998	the	event[46]|time[47]|person[54]|object[56]	new[46]|new[47]|new[54]|new[56]	_	_
7-28	999-1002	JP2	event[46]|time[47]|person[54]|abstract|object[56]	new[46]|new[47]|new[54]|giv|new[56]	coref	8-12
7-29	1003-1008	clone	event[46]|time[47]|person[54]|object[56]	new[46]|new[47]|new[54]|new[56]	_	_
7-30	1009-1011	of	event[46]|time[47]|person[54]|object[56]	new[46]|new[47]|new[54]|new[56]	_	_
7-31	1012-1014	A.	event[46]|time[47]|person[54]|object[56]|person|abstract[58]	new[46]|new[47]|new[54]|new[56]|giv|giv[58]	coref|coref	8-15|8-15[66_58]
7-32	1015-1036	actinomycetemcomitans	event[46]|time[47]|person[54]|object[56]|abstract[58]	new[46]|new[47]|new[54]|new[56]|giv[58]	_	_
7-33	1037-1038	,	_	_	_	_
7-34	1039-1049	possessing	_	_	_	_
7-35	1050-1058	enhanced	abstract[59]	giv[59]	ana	8-7[0_59]
7-36	1059-1068	virulence	abstract[59]	giv[59]	_	_
7-37	1069-1070	.	_	_	_	_

#Text=Based on in vitro studies , it was reported that the JP2 genotype of A. actinomycetemcomitans has a 10 – 20 fold higher lytic activity than the non-JP2 genotypes of A. actinomycetemcomitans .
8-1	1071-1076	Based	_	_	_	_
8-2	1077-1079	on	_	_	_	_
8-3	1080-1082	in	_	_	_	_
8-4	1083-1088	vitro	organization|abstract[61]	new|new[61]	coref|coref	9-3[71_61]|10-14[83_0]
8-5	1089-1096	studies	abstract[61]	new[61]	_	_
8-6	1097-1098	,	_	_	_	_
8-7	1099-1101	it	abstract	giv	_	_
8-8	1102-1105	was	_	_	_	_
8-9	1106-1114	reported	_	_	_	_
8-10	1115-1119	that	_	_	_	_
8-11	1120-1123	the	abstract[64]	new[64]	coref	9-14[75_64]
8-12	1124-1127	JP2	abstract|abstract[64]	giv|new[64]	coref	9-15
8-13	1128-1136	genotype	abstract[64]	new[64]	_	_
8-14	1137-1139	of	abstract[64]	new[64]	_	_
8-15	1140-1142	A.	abstract[64]|person|abstract[66]	new[64]|giv|giv[66]	coref|coref	8-31[70_66]|9-18
8-16	1143-1164	actinomycetemcomitans	abstract[64]|abstract[66]	new[64]|giv[66]	_	_
8-17	1165-1168	has	_	_	_	_
8-18	1169-1170	a	abstract[68]	new[68]	coref	15-28[131_68]
8-19	1171-1173	10	place[67]|abstract[68]	new[67]|new[68]	_	_
8-20	1174-1175	–	place[67]|abstract[68]	new[67]|new[68]	_	_
8-21	1176-1178	20	place[67]|abstract[68]	new[67]|new[68]	_	_
8-22	1179-1183	fold	place[67]|abstract[68]	new[67]|new[68]	_	_
8-23	1184-1190	higher	abstract[68]	new[68]	_	_
8-24	1191-1196	lytic	abstract[68]	new[68]	_	_
8-25	1197-1205	activity	abstract[68]	new[68]	_	_
8-26	1206-1210	than	_	_	_	_
8-27	1211-1214	the	abstract[69]	new[69]	_	_
8-28	1215-1222	non-JP2	abstract[69]	new[69]	_	_
8-29	1223-1232	genotypes	abstract[69]	new[69]	_	_
8-30	1233-1235	of	abstract[69]	new[69]	_	_
8-31	1236-1238	A.	abstract[69]|abstract[70]	new[69]|giv[70]	coref	10-6[81_70]
8-32	1239-1260	actinomycetemcomitans	abstract[69]|abstract[70]	new[69]|giv[70]	_	_
8-33	1261-1262	.	_	_	_	_

#Text=Furthermore , longitudinal clinical studies reported a clear correlation between being carrier of the JP2 genotype of A. actinomycetemcomitans and having an increased risk of developing periodontitis at a young age .
9-1	1263-1274	Furthermore	_	_	_	_
9-2	1275-1276	,	_	_	_	_
9-3	1277-1289	longitudinal	abstract[71]	giv[71]	coref	10-14[84_71]
9-4	1290-1298	clinical	abstract[71]	giv[71]	_	_
9-5	1299-1306	studies	abstract[71]	giv[71]	_	_
9-6	1307-1315	reported	_	_	_	_
9-7	1316-1317	a	abstract[72]	new[72]	_	_
9-8	1318-1323	clear	abstract[72]	new[72]	_	_
9-9	1324-1335	correlation	abstract[72]	new[72]	_	_
9-10	1336-1343	between	abstract[72]	new[72]	_	_
9-11	1344-1349	being	abstract[72]	new[72]	_	_
9-12	1350-1357	carrier	abstract[72]|organization[73]	new[72]|new[73]	_	_
9-13	1358-1360	of	abstract[72]|organization[73]	new[72]|new[73]	_	_
9-14	1361-1364	the	abstract[72]|organization[73]|abstract[75]	new[72]|new[73]|giv[75]	_	_
9-15	1365-1368	JP2	abstract[72]|organization[73]|abstract|abstract[75]	new[72]|new[73]|giv|giv[75]	coref	11-36
9-16	1369-1377	genotype	abstract[72]|organization[73]|abstract[75]	new[72]|new[73]|giv[75]	_	_
9-17	1378-1380	of	abstract[72]|organization[73]|abstract[75]	new[72]|new[73]|giv[75]	_	_
9-18	1381-1383	A.	abstract[72]|organization[73]|abstract[75]|person	new[72]|new[73]|giv[75]|giv	coref	11-42
9-19	1384-1405	actinomycetemcomitans	abstract[72]|organization[73]|abstract[75]	new[72]|new[73]|giv[75]	_	_
9-20	1406-1409	and	abstract[72]	new[72]	_	_
9-21	1410-1416	having	abstract[72]	new[72]	_	_
9-22	1417-1419	an	abstract[72]|abstract[77]	new[72]|new[77]	_	_
9-23	1420-1429	increased	abstract[72]|abstract[77]	new[72]|new[77]	_	_
9-24	1430-1434	risk	abstract[72]|abstract[77]	new[72]|new[77]	_	_
9-25	1435-1437	of	abstract[72]|abstract[77]	new[72]|new[77]	_	_
9-26	1438-1448	developing	abstract[72]|abstract[77]	new[72]|new[77]	_	_
9-27	1449-1462	periodontitis	abstract[72]|abstract[77]|person	new[72]|new[77]|giv	_	_
9-28	1463-1465	at	abstract[72]|abstract[77]	new[72]|new[77]	_	_
9-29	1466-1467	a	abstract[72]|abstract[77]|abstract[79]	new[72]|new[77]|new[79]	_	_
9-30	1468-1473	young	abstract[72]|abstract[77]|abstract[79]	new[72]|new[77]|new[79]	_	_
9-31	1474-1477	age	abstract[72]|abstract[77]|abstract[79]	new[72]|new[77]|new[79]	_	_
9-32	1478-1479	.	_	_	_	_

#Text=Often the leukotoxic potential of A. actinomycetemcomitans is characterized by the leukotoxicity in in vitro studies .
10-1	1480-1485	Often	_	_	_	_
10-2	1486-1489	the	abstract[80]	new[80]	_	_
10-3	1490-1500	leukotoxic	abstract[80]	new[80]	_	_
10-4	1501-1510	potential	abstract[80]	new[80]	_	_
10-5	1511-1513	of	abstract[80]	new[80]	_	_
10-6	1514-1516	A.	abstract[80]|abstract[81]	new[80]|giv[81]	coref	11-42[97_81]
10-7	1517-1538	actinomycetemcomitans	abstract[80]|abstract[81]	new[80]|giv[81]	_	_
10-8	1539-1541	is	_	_	_	_
10-9	1542-1555	characterized	_	_	_	_
10-10	1556-1558	by	_	_	_	_
10-11	1559-1562	the	abstract[82]	new[82]	coref	11-1[85_82]
10-12	1563-1576	leukotoxicity	abstract[82]	new[82]	_	_
10-13	1577-1579	in	_	_	_	_
10-14	1580-1582	in	organization[83]|abstract[84]	giv[83]|giv[84]	coref	16-1[135_84]
10-15	1583-1588	vitro	organization[83]|abstract[84]	giv[83]|giv[84]	_	_
10-16	1589-1596	studies	abstract[84]	giv[84]	_	_
10-17	1597-1598	.	_	_	_	_

#Text=This leukotoxicity is determined by use of cell lysis assays , where human immune cells are exposed either to the bacteria or to purified LtxA , and most often the leukotoxicity is correlated with the JP2 or non-JP2 genotype of the A. actinomycetemcomitans strain .
11-1	1599-1603	This	abstract[85]	giv[85]	coref	11-30[93_85]
11-2	1604-1617	leukotoxicity	abstract[85]	giv[85]	_	_
11-3	1618-1620	is	_	_	_	_
11-4	1621-1631	determined	_	_	_	_
11-5	1632-1634	by	_	_	_	_
11-6	1635-1638	use	abstract[86]	new[86]	_	_
11-7	1639-1641	of	abstract[86]	new[86]	_	_
11-8	1642-1646	cell	abstract[86]|place|object[89]	new[86]|giv|new[89]	coref	13-18
11-9	1647-1652	lysis	abstract[86]|abstract|object[89]	new[86]|giv|new[89]	coref	13-18[119_0]
11-10	1653-1659	assays	abstract[86]|object[89]	new[86]|new[89]	_	_
11-11	1660-1661	,	abstract[86]|object[89]	new[86]|new[89]	_	_
11-12	1662-1667	where	abstract[86]|object[89]	new[86]|new[89]	_	_
11-13	1668-1673	human	abstract[86]|object[89]|animal[90]	new[86]|new[89]|giv[90]	_	_
11-14	1674-1680	immune	abstract[86]|object[89]|animal[90]	new[86]|new[89]|giv[90]	_	_
11-15	1681-1686	cells	abstract[86]|object[89]|animal[90]	new[86]|new[89]|giv[90]	_	_
11-16	1687-1690	are	abstract[86]|object[89]	new[86]|new[89]	_	_
11-17	1691-1698	exposed	abstract[86]|object[89]	new[86]|new[89]	_	_
11-18	1699-1705	either	abstract[86]|object[89]|animal[91]	new[86]|new[89]|new[91]	_	_
11-19	1706-1708	to	abstract[86]|object[89]|animal[91]	new[86]|new[89]|new[91]	_	_
11-20	1709-1712	the	abstract[86]|object[89]|animal[91]	new[86]|new[89]|new[91]	_	_
11-21	1713-1721	bacteria	abstract[86]|object[89]|animal[91]	new[86]|new[89]|new[91]	_	_
11-22	1722-1724	or	_	_	_	_
11-23	1725-1727	to	_	_	_	_
11-24	1728-1736	purified	abstract[92]	giv[92]	coref	15-9[128_92]
11-25	1737-1741	LtxA	abstract[92]	giv[92]	_	_
11-26	1742-1743	,	_	_	_	_
11-27	1744-1747	and	_	_	_	_
11-28	1748-1752	most	_	_	_	_
11-29	1753-1758	often	_	_	_	_
11-30	1759-1762	the	abstract[93]	giv[93]	coref	12-10[101_93]
11-31	1763-1776	leukotoxicity	abstract[93]	giv[93]	_	_
11-32	1777-1779	is	_	_	_	_
11-33	1780-1790	correlated	_	_	_	_
11-34	1791-1795	with	_	_	_	_
11-35	1796-1799	the	abstract[95]	new[95]	_	_
11-36	1800-1803	JP2	abstract|abstract[95]	giv|new[95]	_	_
11-37	1804-1806	or	abstract[95]	new[95]	_	_
11-38	1807-1814	non-JP2	abstract[95]	new[95]	_	_
11-39	1815-1823	genotype	abstract[95]	new[95]	_	_
11-40	1824-1826	of	abstract[95]	new[95]	_	_
11-41	1827-1830	the	abstract[95]|abstract[98]	new[95]|giv[98]	ana	12-3[0_98]
11-42	1831-1833	A.	abstract[95]|person|abstract[97]|abstract[98]	new[95]|giv|giv[97]|giv[98]	coref|coref	12-14|12-15[0_97]
11-43	1834-1855	actinomycetemcomitans	abstract[95]|abstract[97]|abstract[98]	new[95]|giv[97]|giv[98]	_	_
11-44	1856-1862	strain	abstract[95]|abstract[98]	new[95]|giv[98]	_	_
11-45	1863-1864	.	_	_	_	_

#Text=Therefore , it has been the common believe that the leukotoxicity of an A. actinomycetemcomitans strain could be explained by the 530-bp deletion , an explanation supported by recent results presented by Sampathkumar and co-workers .
12-1	1865-1874	Therefore	_	_	_	_
12-2	1875-1876	,	_	_	_	_
12-3	1877-1879	it	abstract	giv	coref	12-13[104_0]
12-4	1880-1883	has	_	_	_	_
12-5	1884-1888	been	_	_	_	_
12-6	1889-1892	the	abstract[100]	new[100]	_	_
12-7	1893-1899	common	abstract[100]	new[100]	_	_
12-8	1900-1907	believe	abstract[100]	new[100]	_	_
12-9	1908-1912	that	_	_	_	_
12-10	1913-1916	the	abstract[101]	giv[101]	coref	13-11[116_101]
12-11	1917-1930	leukotoxicity	abstract[101]	giv[101]	_	_
12-12	1931-1933	of	abstract[101]	giv[101]	_	_
12-13	1934-1936	an	abstract[101]|abstract[104]	giv[101]|giv[104]	_	_
12-14	1937-1939	A.	abstract[101]|person|abstract[104]	giv[101]|giv|giv[104]	coref	13-3
12-15	1940-1961	actinomycetemcomitans	abstract[101]|abstract|abstract[104]	giv[101]|giv|giv[104]	coref	13-4
12-16	1962-1968	strain	abstract[101]|abstract[104]	giv[101]|giv[104]	_	_
12-17	1969-1974	could	_	_	_	_
12-18	1975-1977	be	_	_	_	_
12-19	1978-1987	explained	_	_	_	_
12-20	1988-1990	by	_	_	_	_
12-21	1991-1994	the	event[106]	giv[106]	coref	13-7[115_106]
12-22	1995-2001	530-bp	abstract|event[106]	giv|giv[106]	coref	13-8
12-23	2002-2010	deletion	event[106]	giv[106]	_	_
12-24	2011-2012	,	_	_	_	_
12-25	2013-2015	an	abstract[107]	new[107]	_	_
12-26	2016-2027	explanation	abstract[107]	new[107]	_	_
12-27	2028-2037	supported	abstract[107]	new[107]	_	_
12-28	2038-2040	by	abstract[107]	new[107]	_	_
12-29	2041-2047	recent	abstract[107]|abstract[108]	new[107]|new[108]	coref	13-15[117_108]
12-30	2048-2055	results	abstract[107]|abstract[108]	new[107]|new[108]	_	_
12-31	2056-2065	presented	abstract[107]|abstract[108]	new[107]|new[108]	_	_
12-32	2066-2068	by	abstract[107]|abstract[108]	new[107]|new[108]	_	_
12-33	2069-2081	Sampathkumar	abstract[107]|abstract[108]|person	new[107]|new[108]|new	_	_
12-34	2082-2085	and	abstract[107]|abstract[108]	new[107]|new[108]	_	_
12-35	2086-2096	co-workers	abstract[107]|abstract[108]|person	new[107]|new[108]|new	_	_
12-36	2097-2098	.	_	_	_	_

#Text=However , A. actinomycetemcomitans strains without the 530-bp deletion with high leukotoxicity according to results obtained by cell lysis assay have been reported on .
13-1	2099-2106	However	_	_	_	_
13-2	2107-2108	,	_	_	_	_
13-3	2109-2111	A.	person|abstract[113]	giv|giv[113]	coref|coref	14-7|14-7[124_113]
13-4	2112-2133	actinomycetemcomitans	abstract|abstract[113]	giv|giv[113]	coref	14-8
13-5	2134-2141	strains	abstract[113]	giv[113]	_	_
13-6	2142-2149	without	abstract[113]	giv[113]	_	_
13-7	2150-2153	the	abstract[113]|event[115]	giv[113]|giv[115]	_	_
13-8	2154-2160	530-bp	abstract[113]|abstract|event[115]	giv[113]|giv|giv[115]	_	_
13-9	2161-2169	deletion	abstract[113]|event[115]	giv[113]|giv[115]	_	_
13-10	2170-2174	with	abstract[113]	giv[113]	_	_
13-11	2175-2179	high	abstract[113]|abstract[116]	giv[113]|giv[116]	_	_
13-12	2180-2193	leukotoxicity	abstract[113]|abstract[116]	giv[113]|giv[116]	_	_
13-13	2194-2203	according	abstract[113]|abstract[116]	giv[113]|giv[116]	_	_
13-14	2204-2206	to	abstract[113]|abstract[116]	giv[113]|giv[116]	_	_
13-15	2207-2214	results	abstract[113]|abstract[116]|abstract[117]	giv[113]|giv[116]|giv[117]	coref	18-7[171_117]
13-16	2215-2223	obtained	abstract[113]|abstract[116]|abstract[117]	giv[113]|giv[116]|giv[117]	_	_
13-17	2224-2226	by	abstract[113]|abstract[116]|abstract[117]	giv[113]|giv[116]|giv[117]	_	_
13-18	2227-2231	cell	abstract[113]|abstract[116]|abstract[117]|place|abstract[119]|object[120]	giv[113]|giv[116]|giv[117]|giv|giv[119]|new[120]	coref	16-26[145_120]
13-19	2232-2237	lysis	abstract[113]|abstract[116]|abstract[117]|abstract[119]|object[120]	giv[113]|giv[116]|giv[117]|giv[119]|new[120]	_	_
13-20	2238-2243	assay	abstract[113]|abstract[116]|abstract[117]|object[120]	giv[113]|giv[116]|giv[117]|new[120]	_	_
13-21	2244-2248	have	_	_	_	_
13-22	2249-2253	been	_	_	_	_
13-23	2254-2262	reported	_	_	_	_
13-24	2263-2265	on	_	_	_	_
13-25	2266-2267	.	_	_	_	_

#Text=Furthermore , the leukotoxic potential of A. actinomycetemcomitans strains has been explained by different mechanisms .
14-1	2268-2279	Furthermore	_	_	_	_
14-2	2280-2281	,	_	_	_	_
14-3	2282-2285	the	abstract[121]	new[121]	coref	15-18[129_121]
14-4	2286-2296	leukotoxic	abstract[121]	new[121]	_	_
14-5	2297-2306	potential	abstract[121]	new[121]	_	_
14-6	2307-2309	of	abstract[121]	new[121]	_	_
14-7	2310-2312	A.	abstract[121]|person|abstract[124]	new[121]|giv|giv[124]	coref|coref	15-34|17-31[162_124]
14-8	2313-2334	actinomycetemcomitans	abstract[121]|abstract|abstract[124]	new[121]|giv|giv[124]	coref	15-33[134_0]
14-9	2335-2342	strains	abstract[121]|abstract[124]	new[121]|giv[124]	_	_
14-10	2343-2346	has	_	_	_	_
14-11	2347-2351	been	_	_	_	_
14-12	2352-2361	explained	_	_	_	_
14-13	2362-2364	by	_	_	_	_
14-14	2365-2374	different	abstract[125]	new[125]	_	_
14-15	2375-2385	mechanisms	abstract[125]	new[125]	_	_
14-16	2386-2387	.	_	_	_	_

#Text=A higher expression of the mRNA , encoding the ltxA , has been reported to correspond with a higher leukotoxic potential , but also a variation in the activity of LtxA in some A. actinomycetemcomitans has been reported .
15-1	2388-2389	A	abstract[126]	new[126]	coref	16-13[140_126]
15-2	2390-2396	higher	abstract[126]	new[126]	_	_
15-3	2397-2407	expression	abstract[126]	new[126]	_	_
15-4	2408-2410	of	abstract[126]	new[126]	_	_
15-5	2411-2414	the	abstract[126]|abstract[127]	new[126]|new[127]	coref	16-37[147_127]
15-6	2415-2419	mRNA	abstract[126]|abstract[127]	new[126]|new[127]	_	_
15-7	2420-2421	,	abstract[126]|abstract[127]	new[126]|new[127]	_	_
15-8	2422-2430	encoding	abstract[126]|abstract[127]	new[126]|new[127]	_	_
15-9	2431-2434	the	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|giv[128]	coref	15-31[0_128]
15-10	2435-2439	ltxA	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|giv[128]	_	_
15-11	2440-2441	,	_	_	_	_
15-12	2442-2445	has	_	_	_	_
15-13	2446-2450	been	_	_	_	_
15-14	2451-2459	reported	_	_	_	_
15-15	2460-2462	to	_	_	_	_
15-16	2463-2473	correspond	_	_	_	_
15-17	2474-2478	with	_	_	_	_
15-18	2479-2480	a	abstract[129]	giv[129]	coref	18-28[179_129]
15-19	2481-2487	higher	abstract[129]	giv[129]	_	_
15-20	2488-2498	leukotoxic	abstract[129]	giv[129]	_	_
15-21	2499-2508	potential	abstract[129]	giv[129]	_	_
15-22	2509-2510	,	_	_	_	_
15-23	2511-2514	but	_	_	_	_
15-24	2515-2519	also	_	_	_	_
15-25	2520-2521	a	abstract[130]	new[130]	_	_
15-26	2522-2531	variation	abstract[130]	new[130]	_	_
15-27	2532-2534	in	abstract[130]	new[130]	_	_
15-28	2535-2538	the	abstract[130]|abstract[131]	new[130]|giv[131]	_	_
15-29	2539-2547	activity	abstract[130]|abstract[131]	new[130]|giv[131]	_	_
15-30	2548-2550	of	abstract[130]|abstract[131]	new[130]|giv[131]	_	_
15-31	2551-2555	LtxA	abstract[130]|abstract[131]|abstract	new[130]|giv[131]|giv	coref	16-14
15-32	2556-2558	in	abstract[130]	new[130]	_	_
15-33	2559-2563	some	abstract[130]|abstract[134]	new[130]|giv[134]	coref	16-10[138_134]
15-34	2564-2566	A.	abstract[130]|person|abstract[134]	new[130]|giv|giv[134]	coref	16-10
15-35	2567-2588	actinomycetemcomitans	abstract[130]|abstract[134]	new[130]|giv[134]	_	_
15-36	2589-2592	has	_	_	_	_
15-37	2593-2597	been	_	_	_	_
15-38	2598-2606	reported	_	_	_	_
15-39	2607-2608	.	_	_	_	_

#Text=Only a few studies have compared the leukotoxicity of A. actinomycetemcomitans with the LtxA expression and production defined as a quantification of the LtxA , e.g. , by enzyme-linked immunosorbent assay ( ELISA ) , or mRNA coding for LtxA , but it seems reasonable to assume that the two factors are related .
16-1	2609-2613	Only	abstract[135]	giv[135]	_	_
16-2	2614-2615	a	abstract[135]	giv[135]	_	_
16-3	2616-2619	few	abstract[135]	giv[135]	_	_
16-4	2620-2627	studies	abstract[135]	giv[135]	_	_
16-5	2628-2632	have	_	_	_	_
16-6	2633-2641	compared	_	_	_	_
16-7	2642-2645	the	abstract[136]	new[136]	_	_
16-8	2646-2659	leukotoxicity	abstract[136]	new[136]	_	_
16-9	2660-2662	of	abstract[136]	new[136]	_	_
16-10	2663-2665	A.	abstract[136]|person|abstract[138]	new[136]|giv|giv[138]	coref|coref	17-18|17-17[157_138]
16-11	2666-2687	actinomycetemcomitans	abstract[136]|abstract[138]	new[136]|giv[138]	_	_
16-12	2688-2692	with	_	_	_	_
16-13	2693-2696	the	abstract[140]	giv[140]	coref	17-41[166_140]
16-14	2697-2701	LtxA	abstract|abstract[140]	giv|giv[140]	coref	16-23[143_0]
16-15	2702-2712	expression	abstract[140]	giv[140]	_	_
16-16	2713-2716	and	_	_	_	_
16-17	2717-2727	production	event[141]	giv[141]	_	_
16-18	2728-2735	defined	event[141]	giv[141]	_	_
16-19	2736-2738	as	event[141]	giv[141]	_	_
16-20	2739-2740	a	event[141]|abstract[142]	giv[141]|new[142]	coref	18-23[0_142]
16-21	2741-2755	quantification	event[141]|abstract[142]	giv[141]|new[142]	_	_
16-22	2756-2758	of	event[141]|abstract[142]	giv[141]|new[142]	_	_
16-23	2759-2762	the	event[141]|abstract[142]|abstract[143]	giv[141]|new[142]|giv[143]	coref	16-40[0_143]
16-24	2763-2767	LtxA	event[141]|abstract[142]|abstract[143]	giv[141]|new[142]|giv[143]	_	_
16-25	2768-2769	,	event[141]|abstract[142]	giv[141]|new[142]	_	_
16-26	2770-2774	e.g.	event[141]|abstract[142]|object[145]	giv[141]|new[142]|giv[145]	coref	17-46[169_145]
16-27	2775-2776	,	event[141]|abstract[142]|object[145]	giv[141]|new[142]|giv[145]	_	_
16-28	2777-2779	by	event[141]|abstract[142]|object[145]	giv[141]|new[142]|giv[145]	_	_
16-29	2780-2793	enzyme-linked	event[141]|abstract[142]|object[145]	giv[141]|new[142]|giv[145]	_	_
16-30	2794-2807	immunosorbent	event[141]|abstract[142]|abstract|object[145]	giv[141]|new[142]|new|giv[145]	_	_
16-31	2808-2813	assay	event[141]|abstract[142]|object[145]	giv[141]|new[142]|giv[145]	_	_
16-32	2814-2815	(	_	_	_	_
16-33	2816-2821	ELISA	abstract	new	_	_
16-34	2822-2823	)	_	_	_	_
16-35	2824-2825	,	_	_	_	_
16-36	2826-2828	or	_	_	_	_
16-37	2829-2833	mRNA	abstract[147]	giv[147]	coref	17-47[0_147]
16-38	2834-2840	coding	abstract[147]	giv[147]	_	_
16-39	2841-2844	for	abstract[147]	giv[147]	_	_
16-40	2845-2849	LtxA	abstract[147]|abstract	giv[147]|giv	ana	16-43
16-41	2850-2851	,	_	_	_	_
16-42	2852-2855	but	_	_	_	_
16-43	2856-2858	it	abstract	giv	coref	17-28
16-44	2859-2864	seems	_	_	_	_
16-45	2865-2875	reasonable	_	_	_	_
16-46	2876-2878	to	_	_	_	_
16-47	2879-2885	assume	_	_	_	_
16-48	2886-2890	that	_	_	_	_
16-49	2891-2894	the	abstract[150]	giv[150]	_	_
16-50	2895-2898	two	abstract[150]	giv[150]	_	_
16-51	2899-2906	factors	abstract[150]	giv[150]	_	_
16-52	2907-2910	are	_	_	_	_
16-53	2911-2918	related	_	_	_	_
16-54	2919-2920	.	_	_	_	_

#Text=In the present study , we aimed to investigate if the leukotoxicity of a collection of Ghanaian A. actinomycetemcomitans , serotype b , is related to the LtxA production of the strains determined by Western blotting and ELISA , and LtxA expression as determined in a mRNA expression assay .
17-1	2921-2923	In	_	_	_	_
17-2	2924-2927	the	abstract[151]	new[151]	_	_
17-3	2928-2935	present	abstract[151]	new[151]	_	_
17-4	2936-2941	study	abstract[151]	new[151]	_	_
17-5	2942-2943	,	_	_	_	_
17-6	2944-2946	we	person	acc	ana	18-3
17-7	2947-2952	aimed	_	_	_	_
17-8	2953-2955	to	_	_	_	_
17-9	2956-2967	investigate	_	_	_	_
17-10	2968-2970	if	_	_	_	_
17-11	2971-2974	the	abstract[153]	new[153]	_	_
17-12	2975-2988	leukotoxicity	abstract[153]	new[153]	_	_
17-13	2989-2991	of	abstract[153]	new[153]	_	_
17-14	2992-2993	a	abstract[153]|abstract[154]	new[153]|new[154]	_	_
17-15	2994-3004	collection	abstract[153]|abstract[154]	new[153]|new[154]	_	_
17-16	3005-3007	of	abstract[153]|abstract[154]	new[153]|new[154]	_	_
17-17	3008-3016	Ghanaian	abstract[153]|abstract[154]|person|abstract[157]	new[153]|new[154]|new|giv[157]	appos	17-21[158_157]
17-18	3017-3019	A.	abstract[153]|abstract[154]|person|abstract[157]	new[153]|new[154]|giv|giv[157]	coref	18-37
17-19	3020-3041	actinomycetemcomitans	abstract[153]|abstract[154]|abstract[157]	new[153]|new[154]|giv[157]	_	_
17-20	3042-3043	,	_	_	_	_
17-21	3044-3052	serotype	abstract[158]	giv[158]	coref	18-37[185_158]
17-22	3053-3054	b	abstract[158]	giv[158]	_	_
17-23	3055-3056	,	_	_	_	_
17-24	3057-3059	is	_	_	_	_
17-25	3060-3067	related	_	_	_	_
17-26	3068-3070	to	_	_	_	_
17-27	3071-3074	the	abstract[160]|abstract[161]	new[160]|new[161]	coref|coref	18-31[181_160]|18-31[182_161]
17-28	3075-3079	LtxA	abstract|abstract[160]|abstract[161]	giv|new[160]|new[161]	coref	18-32
17-29	3080-3090	production	abstract[160]|abstract[161]	new[160]|new[161]	_	_
17-30	3091-3093	of	abstract[160]|abstract[161]	new[160]|new[161]	_	_
17-31	3094-3097	the	abstract[160]|abstract[161]|abstract[162]	new[160]|new[161]|giv[162]	_	_
17-32	3098-3105	strains	abstract[160]|abstract[161]|abstract[162]	new[160]|new[161]|giv[162]	_	_
17-33	3106-3116	determined	abstract[160]|abstract[161]|abstract[162]	new[160]|new[161]|giv[162]	_	_
17-34	3117-3119	by	abstract[160]|abstract[161]|abstract[162]	new[160]|new[161]|giv[162]	_	_
17-35	3120-3127	Western	abstract[160]|abstract[161]|abstract[162]|object[163]	new[160]|new[161]|giv[162]|new[163]	_	_
17-36	3128-3136	blotting	abstract[160]|abstract[161]|abstract[162]|object[163]	new[160]|new[161]|giv[162]|new[163]	_	_
17-37	3137-3140	and	abstract[160]|abstract[161]|abstract[162]	new[160]|new[161]|giv[162]	_	_
17-38	3141-3146	ELISA	abstract[160]|abstract[161]|abstract[162]|person	new[160]|new[161]|giv[162]|new	coref	18-11
17-39	3147-3148	,	abstract[161]	new[161]	_	_
17-40	3149-3152	and	abstract[161]	new[161]	_	_
17-41	3153-3157	LtxA	abstract[161]|person|abstract[166]	new[161]|new|giv[166]	coref	17-47[168_166]
17-42	3158-3168	expression	abstract[161]|abstract[166]	new[161]|giv[166]	_	_
17-43	3169-3171	as	abstract[161]|abstract[166]	new[161]|giv[166]	_	_
17-44	3172-3182	determined	abstract[161]|abstract[166]	new[161]|giv[166]	_	_
17-45	3183-3185	in	abstract[161]|abstract[166]	new[161]|giv[166]	_	_
17-46	3186-3187	a	abstract[161]|abstract[166]|object[169]	new[161]|giv[166]|giv[169]	coref	18-13[175_169]
17-47	3188-3192	mRNA	abstract[161]|abstract[166]|abstract|abstract[168]|object[169]	new[161]|giv[166]|giv|giv[168]|giv[169]	coref|coref	18-13|18-13[174_168]
17-48	3193-3203	expression	abstract[161]|abstract[166]|abstract[168]|object[169]	new[161]|giv[166]|giv[168]|giv[169]	_	_
17-49	3204-3209	assay	abstract[161]|abstract[166]|object[169]	new[161]|giv[166]|giv[169]	_	_
17-50	3210-3211	.	_	_	_	_

#Text=Furthermore , we wanted to compare the results obtained by ELISA and mRNA expression assay to elucidate the relationship between the two quantification methods used to determine leukotoxic potential as the LtxA production and expression of A. actinomycetemcomitans , respectively .
18-1	3212-3223	Furthermore	_	_	_	_
18-2	3224-3225	,	_	_	_	_
18-3	3226-3228	we	person	giv	_	_
18-4	3229-3235	wanted	_	_	_	_
18-5	3236-3238	to	_	_	_	_
18-6	3239-3246	compare	_	_	_	_
18-7	3247-3250	the	abstract[171]	giv[171]	_	_
18-8	3251-3258	results	abstract[171]	giv[171]	_	_
18-9	3259-3267	obtained	abstract[171]	giv[171]	_	_
18-10	3268-3270	by	abstract[171]	giv[171]	_	_
18-11	3271-3276	ELISA	abstract[171]|person	giv[171]|giv	_	_
18-12	3277-3280	and	abstract[171]	giv[171]	_	_
18-13	3281-3285	mRNA	abstract[171]|abstract|abstract[174]|object[175]	giv[171]|giv|giv[174]|giv[175]	_	_
18-14	3286-3296	expression	abstract[171]|abstract[174]|object[175]	giv[171]|giv[174]|giv[175]	_	_
18-15	3297-3302	assay	abstract[171]|object[175]	giv[171]|giv[175]	_	_
18-16	3303-3305	to	_	_	_	_
18-17	3306-3315	elucidate	_	_	_	_
18-18	3316-3319	the	abstract[176]	new[176]	_	_
18-19	3320-3332	relationship	abstract[176]	new[176]	_	_
18-20	3333-3340	between	abstract[176]	new[176]	_	_
18-21	3341-3344	the	abstract[176]|abstract[178]	new[176]|new[178]	_	_
18-22	3345-3348	two	abstract[176]|abstract[178]	new[176]|new[178]	_	_
18-23	3349-3363	quantification	abstract[176]|abstract|abstract[178]	new[176]|giv|new[178]	_	_
18-24	3364-3371	methods	abstract[176]|abstract[178]	new[176]|new[178]	_	_
18-25	3372-3376	used	abstract[176]|abstract[178]	new[176]|new[178]	_	_
18-26	3377-3379	to	abstract[176]|abstract[178]	new[176]|new[178]	_	_
18-27	3380-3389	determine	abstract[176]|abstract[178]	new[176]|new[178]	_	_
18-28	3390-3400	leukotoxic	abstract[176]|abstract[178]|abstract[179]	new[176]|new[178]|giv[179]	_	_
18-29	3401-3410	potential	abstract[176]|abstract[178]|abstract[179]	new[176]|new[178]|giv[179]	_	_
18-30	3411-3413	as	_	_	_	_
18-31	3414-3417	the	abstract[181]|abstract[182]	giv[181]|giv[182]	_	_
18-32	3418-3422	LtxA	abstract|abstract[181]|abstract[182]	giv|giv[181]|giv[182]	_	_
18-33	3423-3433	production	abstract[181]|abstract[182]	giv[181]|giv[182]	_	_
18-34	3434-3437	and	abstract[182]	giv[182]	_	_
18-35	3438-3448	expression	abstract[182]|abstract[183]	giv[182]|new[183]	_	_
18-36	3449-3451	of	abstract[182]|abstract[183]	giv[182]|new[183]	_	_
18-37	3452-3454	A.	abstract[182]|abstract[183]|person|abstract[185]	giv[182]|new[183]|giv|giv[185]	_	_
18-38	3455-3476	actinomycetemcomitans	abstract[182]|abstract[183]|abstract[185]	giv[182]|new[183]|giv[185]	_	_
18-39	3477-3478	,	abstract[182]|abstract[183]	giv[182]|new[183]	_	_
18-40	3479-3491	respectively	abstract[182]|abstract[183]	giv[182]|new[183]	_	_
18-41	3492-3493	.	_	_	_	_
